Celltex News
News & Press
Celltex Therapeutics Receives Another FDA Approval: Phase II Clinical Trial Using Mesenchymal Stem Cells (MSCs) as a Prophylactic Against COVID-19
July 1, 2020
Learn MoreRick Perry Discusses Celltex’s COVID-19 Clinical Trials on Fox News TV
June 30, 2020
Former U.S. Secretary of Energy and former Governor of Texas, Rick Perry, was on Fox News TV discussing Celltex’s COVID-19 ongoing clinical trials and the ingenuity that will deliver a victory over this virus.
Learn MoreCelltex & COVID-19 Clinical Trials
June 29, 2020
Celltex has three ongoing COVID-19 clinical trials using Celltex’s TRUECELL™ Mesenchymal Stem Cells (MSCs), a Phase III and two Phase II.
Learn MoreCelltex’s Dr. Derek Guillory on the Erick Erickson Show
April 6, 2020
Dr. Derek W. Guillory, Founder and Medical Director of Root Causes Medicine in San Antonio and Principal Investigator for Celltex’s upcoming clinical trial was recently brought on as a guest of the Erick Erickson Show on WSB Radio.
Learn MoreCelltex has submitted Emergency Expanded Access Clinical Study for Subjects with Coronavirus 2019 (COVID-19) using multiple dose Infusions of Autologous Adipose-Tissue Derived Mesenchymal Stem Cells (ADMSCs)
April 2, 2020
The COVID-19 pandemic has the global medical profession working around the clock looking for vaccines and therapies. On March 21st, 2020, Celltex submitted an emergency expanded access clinical study to the United States Food and Drug Administration (FDA) that would allow patients with COVID-19 to receive infusions of autologous Adipose-tissue derived Mesenchymal Stem Cells (AdMSCs) in the US.
Learn MoreAging & Disease Reports Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia
March 25, 2020
The COVID-19 pandemic has the global medical profession working around the clock looking for vaccines and therapies. The journal Aging & Disease has recently reported on a study that has proven transplantation of mesenchymal stem cells has improved the outcome of 7 patients diagnosed with COVID-19 Pneumonia in Bejing, China.
Learn MoreChinaXiv Reports Clinical Remission of a Critically Ill COVID-19 Patient Treated by Human Umbilical Cord Mesenchymal Stem Cells
March 23, 2020
The COVID-19 pandemic has the global medical profession working around the clock looking for vaccines and therapies. ChinaXiv has performed a recent study that has proven significant improvement of a critically ill COVID-19 patient that was treated with the transfer of human umbilical cord mesenchymal stem cells.
Learn MoreMesenchymal Stem Cell Infusion Shows Promise for Combating Coronavirus (COVID-19)- Induced Pneumonia
March 21, 2020
The COVID-19 pandemic has the global medical profession working around the clock looking for vaccines and therapies. Celltex is continuing to monitor and participate in this promising research.
Learn MoreAn Update from Celltex Therapeutics Regarding COVID-19
March 19, 2020
We have been closely monitoring the guidelines set forth from the Centers for Disease Control (CDC) and the World Health Organization (WHO) in response to COVID-19. The safety and health of our team, clients and community is extremely important to us and because of this, we are taking proper precautions in our corporate office and lab environment.
Learn More